NCT00077298View on ClinicalTrials.gov

Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Recurrent Colon CancerRecurrent Rectal CancerStage IVA Colon CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Rectal Cancer
Interventions
BIOLOGICAL

cetuximab

Given IV

BIOLOGICAL

bevacizumab

Given IV

DRUG

irinotecan hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00077298 - Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter